Therapeutic effects of lithium carbonate combined with 131I on incipient Graves disease accompanied by leukopenia / 中华核医学与分子影像杂志

ABSTRACT

Objective To compare therapeutic effects of lithium carbonate administration (LCA) given in 2 methods and combined with 131I treatment in patients with incipient Graves disease (IGD) accompanied by leukopenia.Methods From January 2014 to January 2016,192 IGD patients with leukopenia were enrolled in this retrospective study,including 49 males,143 females (average age(39.65 ± 12.18) years).All patients did not receive antithyroid drugs (ATD) therapy and were divided into 3 groups by random number table method:group A(131I treatment plus LCA given at the same time for 2 weeks;n=65),group B (LCA given at a week before and after 131I treatment;n=67),control group (only treated with 131I;n=60).Cure rate (3 and 6 months after treatment),WBC (2 weeks,1,3 and 6 months after treatment) and adverse reaction rate (ADR;within 2 weeks after treatment) of 3 groups were analyzed before and after treatment.One-way analysis of variance,the least significant difference t test,x2 test were used.Results Compared with control group,group A and group B showed higher cure rates (3 months after treatment87.7％ (57/ 65),88.1％(59/67),70.0％(42/60);6 months89.2％(58/65),89.6％(60/67),71.7％(43/60);x2 values9.05,9.58,both P＜0.05),higher increasing rates of WBC (3 months after treatment(38.9± 5.1)％,(39.8±6.3)％,(20.2±3.3)％;F=19.87,t values12.15,11.56,all P＜0.01),lower ADR (3.1％(2/65),14.9％ (10/67),30.0％(18/60);x2=17.19,P＜0.05).The ADR of group A was lower than that of group B (x2=4.26,P＜0.05).Conclusion For IGD patients with leukopenia and normal kidney function,the treatment of LCA combined with 131I at the same time for 2 weeks is safe and effective,and patients have less ADR.